FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).

FLT3 (fms-like tyrosine kinase 3) is constitutively activated in about 30% of patients with acute myeloid leukemia (AML) and represents a disease-specific molecular marker. Although FLT3-LM (length mutation) and TKD (tyrosine kinase domain) mutations have been considered to be mutually exclusive, 1% to 2% of patients carry both mutations. However, the functional and clinical significance of this observation is unclear. We demonstrate that FLT3-ITD-TKD dual mutants induce drug resistance toward PTK inhibitors and cytotoxic agents in in vitro model systems. As molecular mechanisms of resistance, we found that FLT3-ITD-TKD mutants cause hyperactivation of STAT5 (signal transducer and activator of transcription-5), leading to upregulation of Bcl-x(L) and RAD51 and arrest in the G(2)M phase of the cell cycle. Overexpression of Bcl-x(L) was identified as the critical mediator of drug resistance and recapitulates the PTK inhibitor and daunorubicin-resistant phenotype in FLT3-ITD cells. The combination of rapamycin, a selective mTOR inhibitor, and FLT3 PTK inhibitors restored the drug sensitivity in FLT3 dual mutant-expressing cells. Our data provide the molecular basis for understanding clinical FLT3 PTK inhibitor resistance and point to therapeutical strategies to overcome drug resistance in patients with AML.

[1]  G. Ehninger,et al.  Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .

[2]  C. Peschel,et al.  BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study , 2002, The Lancet.

[3]  J. Radich,et al.  Novel FLT3 point mutations within exon  14 found in patients with acute myeloid leukaemia , 2004, British journal of haematology.

[4]  C. Sawyers,et al.  Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[6]  Claude Preudhomme,et al.  Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. , 2002, Blood.

[7]  R. Herrmann,et al.  High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. , 2002, Blood.

[8]  Randy Allred,et al.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.

[9]  W. Berdel,et al.  Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. , 2000, Blood.

[10]  M. McMullin,et al.  Bcl-2 Family Members As Prognostic Indicators in AML , 2002, Hematology.

[11]  M. Caligiuri,et al.  Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. , 2001, Cancer research.

[12]  K.,et al.  Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells , 2000, British journal of haematology.

[13]  W. Hiddemann,et al.  TGF-β inhibits growth and induces apoptosis in leukemic B cell precursors , 1997, Leukemia.

[14]  M. Kutlubaev,et al.  [The influence of some psychotropic drugs on the processes of free radical oxidation in model systems]. , 2005, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova.

[15]  Martin Dugas,et al.  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. , 2002 .

[16]  T. Myers,et al.  An informatics approach identifying markers of chemosensitivity in human cancer cell lines. , 2000, Cancer research.

[17]  W. Hofmann,et al.  Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. , 2003, Blood.

[18]  J. Blenis,et al.  Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression , 2004, Oncogene.

[19]  Nick Holford,et al.  Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. , 2006, Blood.

[20]  D. Rees,et al.  FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high‐risk group , 2000, British journal of haematology.

[21]  D. Gilliland,et al.  FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. , 2002, Blood.

[22]  D. Ross,et al.  Novel mechanisms of drug resistance in leukemia , 2000, Leukemia.

[23]  B. Löwenberg,et al.  Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene , 2000, Leukemia.

[24]  D. Neuberg,et al.  Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Mui,et al.  STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells , 1999, The EMBO journal.

[26]  Fayza Daboussi,et al.  DNA double-strand break repair signalling: the case of RAD51 post-translational regulation. , 2002, Cellular signalling.

[27]  P. Bolufer,et al.  Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. , 2003, Haematologica.

[28]  山本 幸也,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies , 2002 .

[29]  J. Reilly,et al.  Identification of novel FLT‐3 Asp835 mutations in adult acute myeloid leukaemia , 2001, British journal of haematology.

[30]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[31]  E. D. de Vries,et al.  The Role of Drug Efflux Pumps in Acute Myeloid Leukemia , 2002, Leukemia & lymphoma.

[32]  W. Hiddemann,et al.  The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. , 2003, Blood.

[33]  T. Naoe,et al.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. , 1999, Blood.

[34]  M. V. Heiden,et al.  Bcl-xL Regulates the Membrane Potential and Volume Homeostasis of Mitochondria , 1997, Cell.

[35]  R. Fishel,et al.  BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. , 2001, Molecular cell.

[36]  D. Small,et al.  Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation , 2000, Leukemia.

[37]  G. Seitz,et al.  The prognostic value of Bcl-XL gene expression for remission induction is influenced by cytogenetics in adult acute myeloid leukemia. , 2001, Haematologica.

[38]  A. Sancar,et al.  Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. , 2004, Annual review of biochemistry.

[39]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[40]  M. Hidalgo,et al.  The rapamycin-sensitive signal transduction pathway as a target for cancer therapy , 2000, Oncogene.

[41]  E. Estey,et al.  Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 , 2004 .

[42]  T. Helleday,et al.  RAD51 is involved in repair of damage associated with DNA replication in mammalian cells. , 2003, Journal of molecular biology.

[43]  W. El-Deiry,et al.  BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. , 1995, Blood.

[44]  J. Reilly.  Class III receptor tyrosine kinases: role in leukaemogenesis , 2002, British journal of haematology.

[45]  S. West,et al.  Telomere Maintenance Requires the RAD51D Recombination/Repair Protein , 2004, Cell.

[46]  W. Hiddemann,et al.  Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. , 2004, Blood.

[47]  S. de Vos,et al.  Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. , 2002, Blood.

[48]  P. Bolufer,et al.  Incidence and prognostic value of FLT 3 internal tandem duplication and D 835 mutations in acute myeloid leukemia , 2002 .

[49]  T. Naoe,et al.  Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines , 2000, Oncogene.